A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration

Trial Profile

A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2017

At a glance

  • Drugs Aflibercept/nesvacumab (Primary) ; Aflibercept
  • Indications Age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms ONYX
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 05 Jul 2017 Planned End Date changed from 1 Nov 2017 to 1 Oct 2017.
    • 05 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Oct 2017.
    • 09 Feb 2017 According to a Regeneron Pharmaceuticals media release, results from this trial are expected in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top